ストックスクリーナーアプリを入手
4.30
5.70%
-0.26
アフターアワーズ：
4.28
-0.02
-0.47%
前日終値:
$4.56
開ける：
$4.29
24時間の取引高:
3.10M
Relative Volume:
0.83
時価総額：
$578.67M
収益：
-
当期純損益:
$-217.44M
株価収益率:
-1.9816
EPS:
-2.17
ネットキャッシュフロー:
$-205.20M
1週間 パフォーマンス:
-10.79%
1か月 パフォーマンス:
-31.96%
6か月 パフォーマンス:
+155.95%
1年 パフォーマンス:
+8.59%
1日の値動き範囲:
$4.27
$4.555
1週間の範囲:
$4.27
$5.025
52週間の値動き範囲:
$1.11
$6.94
Prime Medicine Inc Stock (PRME) Company Profile
PRME を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
4.30 | 812.93M | 0 | -217.44M | -205.20M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-27 | ダウングレード | Citigroup | Buy → Neutral |
| 2025-05-20 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-05-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-12-10 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-05-20 | 開始されました | H.C. Wainwright | Buy |
| 2024-05-16 | アップグレード | Citigroup | Neutral → Buy |
| 2024-04-22 | 開始されました | Chardan Capital Markets | Buy |
| 2024-04-08 | 開始されました | TD Cowen | Buy |
| 2024-04-03 | 開始されました | Wedbush | Outperform |
| 2024-01-16 | ダウングレード | Stifel | Buy → Hold |
| 2023-12-08 | 開始されました | Citigroup | Neutral |
| 2023-10-09 | 開始されました | BMO Capital Markets | Outperform |
| 2023-07-31 | 開始されました | Guggenheim | Buy |
| 2023-04-18 | 開始されました | Stifel | Buy |
| 2022-11-14 | 開始されました | Goldman | Neutral |
| 2022-11-14 | 開始されました | JP Morgan | Overweight |
| 2022-11-14 | 開始されました | Jefferies | Buy |
| 2022-11-14 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Prime Medicine Inc (PRME) 最新ニュース
Prime Medicine (NASDAQ:PRME) Trading Down 9.1%What's Next? - MarketBeat
Prime Medicine (NYSE:PRME) Stock Price Down 8.8%Here's Why - MarketBeat
Prime Medicine appoints Matthew Hawryluk as chief business officer By Investing.com - Investing.com Australia
Levin Capital Strategies L.P. Increases Stock Holdings in Prime Medicine, Inc. $PRME - MarketBeat
Tick level data insight on Prime Medicine Inc. volatilityGold Moves & Daily Entry Point Alerts - newser.com
Is Prime Medicine Inc. stock a buy in volatile markets2025 Growth vs Value & Consistent Income Trade Recommendations - newser.com
Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer - citybiz
Prime Medicine (PRME) Competitors and Alternatives 2025 - MarketBeat
How institutional ownership impacts Prime Medicine Inc. stock2025 Stock Rankings & Smart Money Movement Tracker - newser.com
Prime Medicine appoints Matthew Hawryluk as chief business officer - Investing.com
Prime Medicine, Inc. Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer - Quiver Quantitative
Prime Medicine (NASDAQ: PRME) names Matthew Hawryluk CBO; >$2.5B in deals at Gritstone - Stock Titan
Why Prime Medicine Inc. stock appeals to analystsMarket Movement Recap & Weekly Market Pulse Alerts - newser.com
Will Prime Medicine Inc. stock outperform growth indexesMarket Growth Report & Low Drawdown Momentum Trade Ideas - newser.com
Smart tools for monitoring Prime Medicine Inc.’s price actionWeekly Investment Summary & Fast Exit and Entry Strategy Plans - newser.com
Price momentum metrics for Prime Medicine Inc. explainedMarket Risk Summary & Daily Market Momentum Tracking - newser.com
Is Prime Medicine Inc. stock supported by strong fundamentalsJuly 2025 News Drivers & Smart Money Movement Alerts - newser.com
How Prime Medicine Inc. stock reacts to job market data2025 Momentum Check & Expert Curated Trade Setup Alerts - newser.com
How Prime Medicine Inc. stock performs in weak economyJuly 2025 Spike Watch & Weekly Market Pulse Alerts - newser.com
Combining price and volume data for Prime Medicine Inc.Buy Signal & Technical Pattern Based Signals - newser.com
Momentum divergence signals in Prime Medicine Inc. chartMarket Trend Summary & Verified Swing Trading Watchlists - newser.com
Comparing Prime Medicine Inc. in custom built stock radarsWeekly Stock Recap & Consistent Growth Equity Picks - newser.com
Technical signs of recovery in Prime Medicine Inc.Market Risk Summary & Technical Confirmation Alerts - newser.com
Prime Medicine’s Price Target Revision Sparks Market Interest - StocksToTrade
Prime Medicine Eyes Expansion with Strategic Partnerships and Investor Engagement - timothysykes.com
Prime Medicine, Inc. (NYSE:PRME) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Prime Medicine’s Investor Activities and Upcoming Developments Boost Market Interest - StocksToTrade
Prime Medicine Stock Poised for Strategic Growth With New Developments - timothysykes.com
Prime Medicine (NASDAQ:PRME) Shares Up 9.9%Time to Buy? - MarketBeat
Prime Medicine (NYSE:PRME) Trading 11.9% HigherWhat's Next? - MarketBeat
Sumitomo Mitsui Trust Group Inc. Has $3.94 Million Position in Prime Medicine, Inc. $PRME - MarketBeat
PRME Stock Surge: A Buying Opportunity? - StocksToTrade
Institutional investors in Prime Medicine, Inc. (NASDAQ:PRME) see US$174m decrease in market cap last week, although long-term gains have benefitted them. - Yahoo Finance
Does Prime Medicine Inc. qualify in momentum factor screeningEarnings Beat & Weekly High Potential Stock Alerts - newser.com
Using economic indicators to assess Prime Medicine Inc. potentialWeekly Profit Report & AI Based Buy and Sell Signals - newser.com
IQ EQ FUND MANAGEMENT IRELAND Ltd Reduces Stock Holdings in Prime Medicine, Inc. $PRME - MarketBeat
Published on: 2025-10-31 03:29:26 - newser.com
Can Prime Medicine Inc. stock outperform in 2025 bull marketTrend Reversal & Daily Technical Forecast Reports - newser.com
Prime Medicine to Host Virtual KOL Event to Showcase Wilson’s Disease Strategy - The Manila Times
Prime Medicine (NASDAQ: PRME) to file IND/CTA for PM577 in H1 2026 for Wilson’s Disease - Stock Titan
Prime Medicine Inc (PRME) 財務データ
収益
当期純利益
現金流量
EPS
Prime Medicine Inc (PRME) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| NELSEN ROBERT | Director |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| ARCH Venture Partners XII, LLC | 10% Owner |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| ARCH Venture Partners X, LLC | 10% Owner |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| Liu David R. | 10% Owner |
Jun 30 '25 |
Buy |
2.52 |
21,000 |
52,830 |
20,240,945 |
| Liu David R. | 10% Owner |
Jun 23 '25 |
Buy |
2.16 |
21,000 |
45,402 |
20,219,945 |
| Liu David R. | 10% Owner |
Jun 16 '25 |
Buy |
1.49 |
21,000 |
31,196 |
20,198,945 |
| Liu David R. | 10% Owner |
Jun 11 '25 |
Buy |
1.60 |
21,000 |
33,590 |
20,177,945 |
| Brudnick Richard | Chief Business Officer |
May 20 '25 |
Buy |
1.19 |
20,000 |
23,790 |
20,000 |
| LEE ANN L. | Chief Technical Officer |
May 21 '25 |
Buy |
1.13 |
100,000 |
113,000 |
100,000 |
| Reine Allan | Chief Executive Officer |
May 21 '25 |
Buy |
1.18 |
125,000 |
147,150 |
125,000 |
1.45%
0.86%
大文字化:
|
ボリューム (24 時間):